Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1

Cancer Gene Therapy

Volumn 11, Issue 11, 2004, Pages 757-766

  Noblitt, Loren W ^a,b   Bangari, Dinesh S ^a,b   Shukla, Shruti ^a,b   Knapp, Deborah W ^b   Mohammed, Sulma ^b   Kinch, Michael S ^c   Mittal, Suresh K ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Adenoviral vectors; Breast cancer; Delivery vehicle; EphA2; EphrinA 1

Indexed keywords

ADENOVIRUS VECTOR; EPHRIN A1; EPHRIN A2; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL INTERACTION; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR CELL;

ADENOVIRIDAE; BREAST NEOPLASMS; CELL LINE, TUMOR; EPHRIN-A1; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; PHOSPHORYLATION; RECEPTOR, EPHA2;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MINK CELL FOCUS-FORMING VIRUS;

EID: 4444257965     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700761     Document Type: Article

References (42)

1. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev. 1995;16:559-589.
2. Zelmski DP, Zantek ND, Stewart JC, et al. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61:2301-2306.
3. Rosenberg IM, Goke M, Kanai M, et al. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol. 1997;273: G824-G832.
4. Easty DJ, Guthrie BA, Maung K, et al. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res. 1995;55:2528-2532.
5. Andres AC, Zuercher G, Djonov V, et al. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int J Cancer. 1995;63: 288-296.
6. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 1999;41:275-280.
7. Dohn M, Jiang J, Chen X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene. 2001;20:6503-6515.
8. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol. 2001;3:527-530.
9. Coffman KT, Hu M, Carles-Kinch K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003;63:7907-7912.
10. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metast. 2003;20:59-68.
11. Bartley TD, Hunt RW, Welcher AA, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature. 1994;368:558-560.
12. Zisch AH, Pazzagli C, Freeman AL, et al. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene. 2000;19: 177-187.
13. Kullander K, Mather NK, Diella F, et al. Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron. 2001;29: 73-84.
14. Walker-Daniels J, Hess AR, Hendrix MJC, et al. Differential regulation of EphA2 in normal and malignant cells [Review]. Am J Pathol. 2003;162:1037-1042.
15. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002;277:46974-46979.
16. Stewart AK, Lassam NJ, Quirt IC. et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Therapy. 1999;6:350-363.
17. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res. 2000;6: 3395-3399.
18. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res. 2000;55:479-505.
19. Liu Y, Huang H, Saxena A, et al. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther. 2002;9:533-542.
20. St George JA. Gene therapy progress and prospects: adenoviral vectors [Review]. Gene Therapy. 2003;10: 1135-1141.
21. Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002;9:202-208.
22. Ambar BB, Frei K, Malipiero U, et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther. 1999;10: 1641-1648.
23. Parks R, Evelegh C, Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Therapy. 1999;6: 1565-1573.
24. Trudel S, Li Z, Dodgson C, et al. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. Leukemia. 2001;15:846-854.
25. Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther. 2001;8:361-370.
26. Akbulut H, Zhang L, Tang Y, et al. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther. 2003;10:388-395.
27. Ng P, Parks RJ, Cummings DT, et al. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther. 1999;10:2667-2672.
28. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res. 2004, in press.
29. Zantek ND, Azimi M, Fedor-Chaiken M, et al. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell-Growth Differ. 1999;10:629-638.
30. Price JE. Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. J Natl Cancer Inst 1986;77:529-535.
31. Carles-Kinch K, Kilpatrick KE, Stewart JC, et al. Anti-body targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002;62: 2840-2847.
32. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
33. Palmer K, Hitt M, Emtage PC, et al. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Therapy. 2001;8:282-290.
34. Ding Y, Wen Y, Spohn B, et al. Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer. Clin Cancer Res. 2002;8:3290-3297.
35. Vlachaki MT, Chhikara M, Aguilar L, et al. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys. 2001;51:1008-1017.
36. Kikawa KD, Vidale DR, Van Etten RL, et al. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem. 2002;277: 39274-39279.
37. Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-74.
38. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet. 1996;22: 477-488.
39. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods of Molecular Biology: Gene Transfer and Expression Protocols. Totowa: Humana Press: 1991:109-128.
40. Kinch MS, Kilpatrick KE, Zhong C. Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. Hybridoma. 1998;17:227-235.
41. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456-467.
42. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York: Cold Harbor Press; 2001.